What Ranbaxy's Fraud Says About the State of Big Pharma Research
When it comes to medical research, the government has little involvement, leaving pharmaceuticals to underwrite objective clinical trials of the drugs they intend to sell.
And that was just 2007.
At the same time, the Food and Drug Administration was already two years into an investigation of massive fraud committed by Ranbaxy that would lead to the company pleading guilty to seven felonies in May 2103. The $500 million settlement -- including $150 million in criminal fine and forfeiture payments and $350 million in civil claims -- was the largest ever with a generic drugmaker over drug safety.
Many Americans may not know the company by name, but we are certainly familiar with its products. Ranbaxy exports to the US, among 125 countries, generic versions of AstraZeneca's (NYSE:AZN) Nexium, Eli Lilly & Company’s (NYSE:LLY) Prozac, Baxter Healthcare Corp’s (NYSE:BAX) Ativan, and GlaxoSmithKline’s (NYSE:GSK) Imitrex and Valtrex.
Ranbaxy’s generic of Pfizer’s (NYSE:PFE) Lipitor was recalled in 2012 for containing glass particles in its raw ingredients.
But this safety breach merely scratches the surface of Ranbaxy’s violations for selling adulterated drugs. On at least 15 of Ranbaxy’s new drug applications, the FDA found over 1,600 data errors. The bioequivalence figures -- needed to prove a generic is at least an 80% chemical match of the branded drug -- either didn’t exist or were cooked up by the company entirely.
Vince Fabiano, a former vice president of Ranbaxy, told CBS News, "In essence, they used the fraud as a competitive advantage to build and grow the business here in the US." He added, "Let's say you're treated with a generic cancer drug and -- and your cancer -- progresses. Is it because of the drug? Is it because of the disease process? No one would know. And it's harm that in many cases would not be detectable."
The FDA didn’t discover Ranbaxy’s wrongdoings on its own; it took an executive and chemical engineer within the company to expose the deception. In fact, when it comes to medical research, the government has very little to no involvement, leaving pharmaceutical companies to underwrite objective clinical trials of the very drugs they intend to sell.
For the past few years, Roche (OTCMKTS:RHHBY), the Swiss company that manufactures and markets Tamiflu, has been under fire for presenting misleading research to nations worldwide about the antiviral drug’s ability to control the flu. Since 2005, the US government has spent billions stockpiling Tamiflu based on a paper that analyzed 10 studies, all of them funded by Roche.
According to sources who spoke to us on background, the FDA simply lacks the resources to independently test drug safety and efficacy. The research and development costs to bring a drug to market can run as much as a billion dollars. Once a drug has been approved, organizations like the National Institutes of Health sometimes fund further research in academic settings, and trials may also be initiated by investigators for publication in medical journals, but drug companies often pay for these studies as well.
Big Pharma’s conflict of interest between research and profit hasn’t always been the status quo. In his book, Overdosed America, John Abramson, M.D., explains, "As the function of medical research in our society has been transformed from a fundamentally academic and scientific activity to a fundamentally commercial activity, the context in which the research is done has similarly changed: First in universities funded primarily by public sources, then in universities funded primarily by commercial sources, then by independent for-profit research organizations contracting directly with drug companies.”
Three of the four major global advertising holding companies -- Omnicom (NYSE:OMC), Interpublic Group of Companies, Inc. (NYSE:IPG), and WPP (NASDAQ:WPPGY) have either bought or invested in the companies that perform clinical trials.
Though the prohibitive costs of conducting drug research is surely beyond the scope of the FDA, the government has other incentives to stay out of it -- namely, politicians’ campaign coffers generously filled by a well-funded pharmaceutical lobby.
Ranbaxy alone has spent nearly $2.5 million on lobbying since 2010.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.